Article title: Towards a better implementation of treat-to-target strategy in rheumatoid arthritis: a comparison of two real-world cohorts

Authors and affiliations:

Hong Huang PhD, Wenhui Xie PhD, Yan Geng MD, Yong Fan PhD, Yu Wang MD, Juan Zhao MD, Zhuoli Zhang MD, PhD.

Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China

Correspondence to:

Prof. Dr. Zhuoli Zhang, MD. PhD,

Department of Rheumatology and Clinical Immunology,

Peking University First Hospital,

Beijing 100034, China.

zhuoli.zhang@126.com

Supplementary Materials Table S1. DAS and CDAI scores of the two cohorts during follow up, median (IQR)

	Unmatched cohort				Matched cohort			
	TARRA cohort (n=389 at baseline)		CENTRA cohort (n=111 at baseline)		p value	TARRA cohort (n=271 at baseline)		CENTRA cohort (n=102 at baseline)		p value
DAS28 at 3-month	n=343	3 (1.7)	n=106	2.3 (1.3)	0.001	n=241	3 (1.8)	n=97	2.3 (1.2)	0.001
CDAI at 3-month	n=343	6 (7)	n=106	3.3 (5)	< 0.001	n=241	6 (7)	n=97	3 (4)	< 0.001
DAS28 at 6-month	n=365	2.6 (1.4)	n=102	2.3 (1.3)	0.007	n=253	2.6 (1.6)	n=93	2.3 (1.3)	0.005
CDAI at 6-month	n=365	4 (6)	n=102	3 (5.5)	0.002	n=253	4 (6)	n=93	3 (5.5)	0.001
DAS28 at 12-month	n=365	2.4 (1.4)	n=111	2 (1.3)	< 0.001	n=271	2.4 (1.5)	n=102	2 (1.2)	< 0.001
CDAI at 12-month	n=389	2.5 (4)	n=111	2 (4)	< 0.001	n=271	3 (4)	n=102	1.8 (3.6)	< 0.001
DAS28 at 24-month	n=283	2.2 (1.1)	n=67	2 (1)	0.012	n=185	2.2 (1.1)	n=62	2 (1)	0.014
CDAI at 24-month	n=283	2 (3)	n=67	1 (3.5)	0.003	n=185	2 (3)	n=62	1 (3)	0.002

Supplementary Materials Figure S1. Trends in disease activity scores according to DAS28 (A) and CDAI (B) over 2 years in the TARRA cohort and CENTRA cohort.

Supplementary Materials Figure 2. Trends in the percentage of remission, low, moderate and high disease activity over 2 years by DAS28 (A) and CDAI (B) in the TARRA and CENTRA cohort.